411080 — Sands Lab Income Statement
0.000.00%
Last trade - 00:00
- KR₩120bn
- KR₩89bn
- KR₩12bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,573 | 5,247 | 5,414 | 9,300 | 11,722 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,255 | 5,340 | 4,925 | 7,210 | 12,606 |
Operating Profit | 317 | -93 | 489 | 2,089 | -884 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 370 | -47.2 | 546 | 2,114 | 13 |
Provision for Income Taxes | |||||
Net Income After Taxes | 370 | -47.2 | 734 | 2,155 | 439 |
Net Income Before Extraordinary Items | |||||
Net Income | 370 | -47.2 | 734 | 2,155 | 439 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 370 | -47.2 | 734 | 2,155 | 439 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 28.7 | -3.65 | 56.8 | 167 | 33 |
Dividends per Share |